GlassScriptPhysician profile
William Buckett
NPI 1851481824
$1,176.43
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $491 · 2022: $260 · 2023: $385 · 2024: $40.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.26 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $523.96 | 2021-2023 | |
| Pfizer INC. | $153.32 | 2023-2024 | |
| Ucb, INC. | $144.77 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $72.91 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.66 | 2022 | |
| Genzyme Corporation | $51.92 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $32.80 | 2022-2023 | Keveyis |
| Amgen INC. | $26.23 | 2021-2022 | |
| Kyowa Kirin, INC. | $19.27 | 2023 | Nourianz |
| Lilly USA, LLC | $18.16 | 2023 | Amyvid |
| Avanir Pharmaceuticals, INC. | $18.06 | 2022 | |
| Grifols USA, LLC | $17.81 | 2024 | Gamunex-C |
| Sunovion Pharmaceuticals INC. | $12.89 | 2021 | |
| Celgene Corporation | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Buckett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.